AI
PRTK

Atom Investors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Atom Investors’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-21,809
Closed -$149K – 409
2021
Q2 		$149K Buy
+21,809
New +$176K 0.02% 225

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Atom Investors's PRTK Position: Q3 2021 in Review

Atom Investors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2021, closing a stake of 21,809 shares — an estimated $149K sold.

Atom Investors first reported a position in PRTK in Q2 2021 and held it in 1 quarter. The position peaked at $149K in Q2 2021. 105 funds tracked by Wall St. Rank hold PRTK as of Q3 2021.

  • Atom Investors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Atom Investors sold 21,809 Paratek Pharmaceuticals, Inc. shares in Q3 2021, an estimated $149K.
  • Atom Investors first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2021 and held it in 1 quarter.
  • Atom Investors's Paratek Pharmaceuticals, Inc. position peaked at $149K in Q2 2021.
  • 105 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2021.

Based on Atom Investors's 13F filing for Q3 2021, filed 15 Nov 2021.